New Colloboration with IPATH solutions to provide HTA Expertise

Geoffroy “Jeff” Coteur, iPATH Solutions ™ – a senior leader in market access, pricing and HEOR strategy and Bottomley Consulting Group link up.

iPATH Solutions’ mission is to ensure patients access to pharmaceutical & medical innovation while driving the growth of our clients’ businesses. We help our clients to overcome access hurdles by developing future-proof HEOR, market access & pricing strategies for innovative assets, providing excellence in commercial launch execution tailored to the specific HTAs & payers, and building the client’s in-house functional expertise in Value & Access.

Please contact iPATH Solutions™ directly, to learn more about how they can assist you in achieving your goals or speak to Bottomley Consulting Group to know more about our colloborations.

 

Bottomley Consulting Group join forces with 5P Health Care Solutions Inc

5P Health Care Solutions Inc and Bottomley Consulting Group proudly announce their cooperation on 5Proms management and research. Putting patients’ outcomes at the center of optimal care delivery and innovation of novel therapies is at the heart of what is often referred to as Value-Based Health Care. “As a trained physician and a former drug development executive in pharma, I believe that outcomes that matter to patients are the cornerstone of value generation for all 5P actors: pharma, payers, policymaker, providers and patients,” says Dr Verena Voelter, CEO and Founder of the boutique consulting firm 5P Health Care Solutions. Partnering with top experts in the field of PRO research – spanning from IT & software data solutions to outcomes analytics & benchmark scoring – is a key component of the 5Proms service which develops outcomes models in a prospective way. Dr Andrew Bottomley as the Founder of the Bottomley Consulting Group is excited to join this practice: “bringing my expertise as a leader in the field of Health-Related Quality of Life research to this unique approach of putting PROMS as a primary endpoint in prospective data collection, is a great way to make an impact directly to where it matters: at the point of care, with the patient.”
Interested clients can request additional info material at info@5PHealthCareSolutions.com and at https://5phealthcaresolutions.com/index.php/5proms/ or via Andrew Bottomley

New Partnerships - With Leading Medical And Ethics Consultancy, Dr. Joana Namorado

New Partnerships: Breakthrough Partnership with Leading Medical and Ethics Consultancy

Bottomley Consulting Group is thrilled to announce its strategic partnership with Citolab Lda, an esteemed medical consultancy firm headquartered in Lisbon, Portugal. 

Citolab, under the visionary leadership of Dr. Joana Namorado, a distinguished medical doctor specializing in cytopathology, offers invaluable clinical support and is renowned for its expertise in medical ethics. This expertise is invaluable in the pharmaceutical and clinical research sectors, where adherence to ethical standards is paramount.

Dr. Namorado’s illustrious career, spanning various regions including Portugal, the United Kingdom, India, and Belgium, has been marked by active participation in numerous clinical studies. Particularly in the field of oncology, her contributions have been invaluable. This directly benefits pharmaceutical companies engaged in cutting-edge research, as her insights can lead to groundbreaking discoveries and treatments.

However, Dr. Namorado’s influence extends beyond the confines of a clinical laboratory. Her service history with the European Commission, where she played key roles in drafting significant EU legislation related to Science, Technology, and Enterprise, is a testament to her commitment to advancing healthcare and ethical standards. This legislative work directly impacts pharmaceutical companies by shaping the regulatory environment they operate in.

Dr. Namorado’s expertise was instrumental in the review and transition of critical directives such as Personal Data, Clinical Trials, and Blood and Tissue into regulations. This regulatory stability is vital for companies involved in clinical trials, ensuring compliance and streamlined processes.

Her role as an Official in the EU Commission’s Research and Health portfolio further emphasizes her impact on the pharmaceutical industry. Her responsibilities in Cancer and Ethics, Stem Cells, and Gender-related matters directly influence the ethical and regulatory landscape within which pharmaceutical companies operate, ensuring that research is conducted responsibly and ethically. Dr. Namorado’s current advisory roles in multiple EU and Eurpean Research Council projects, along with her contributions to European projects like RESTORE, hPSCreg, and EJP-RD, underscore her continued dedication to shaping the future of healthcare and research. Her collaboration with esteemed institutions, Members of the European Parliament, and organizations like the Red Cross Portugal and BCRT, further bridges the gap between research and application, benefiting both companies and patients.

The synergy between Bottomley Consulting Group and Citolab Lda, under Dr. Joana Namorado’s leadership, creates a powerful force in the realms of clinical support, ethics consultancy, and research. We trust this collaboration is poised to deliver exceptional value to pharmaceutical companies, clinical trials, and research initiatives alike. 

 

 Forging a New Strategic Partnership with Global Impact- Genetics expertise

Dr Kristel Van Steen, Ph.D.

 

In today’s rapidly evolving landscape, the demand for expertise in Genetics and statistical methods has reached unprecedented heights, particularly in the pharmaceutical, biotech, and startup sectors. We are thrilled to announce a groundbreaking collaboration that promises to redefine the future of genetic research and statistical analysis, with profound relevance to these industries.

Embarking on this new chapter, we proudly join forces with the distinguished Dr. Kristel Van Streen, a true luminary in the field of statistical genetics with an illustrious career spanning over two decades. Dr. Van Streen has dedicated her life’s work to the advancement of interdisciplinary research, bringing together the realms of genetics and statistics in pioneering ways and involving the use of HRQOL data.

Pharmaceutical companies, biotech giants, and innovative startups, take note: Dr. Kristel Van Streen’s mission is aligned with your needs in today’s ever-competitive landscape. For years, she has been a guiding light, empowering biomedical researchers within your organizations to navigate the complexities of their investigations and to forge new paths where necessary. Her unparalleled expertise has been a driving force behind the progress of countless projects, reshaping the very fabric of genetic research and development.

Today, Dr. Van Streen’s pursuits are at the forefront of innovation and directly applicable to your endeavors. She is dedicated to co-designing optimized network-oriented strategies and crafting implementation protocols that harness the power of an individual’s unique omics or microbiome profile. These groundbreaking efforts are poised to revolutionize precision medicine, offering tailor-made solutions and breakthroughs for pharmaceutical research, biotech innovations, and the cutting-edge projects of startups.

Our partnership with Dr. Kristel Van Streen is a testament to our commitment to excellence and innovation in the field of genetics and statistical methods, with a direct impact on pharmaceutical companies, biotech leaders, and forward-thinking startups. Together, we are poised to embark on a journey of discovery, pushing the boundaries of what is possible in the pursuit of scientific knowledge, and directly contributing to the growth and success of your organizations.

To learn more about Dr. Kristel Van Streen and the incredible work she is spearheading, we invite you to visit her profile at http://bio3.giga.ulg.ac.be/. Join us on this extraordinary journey towards a future where precision medicine and public health take center stage, and together, we will make a profound impact on the world of genetic research and its crucial relevance to the pharmaceutical, biotech, and startup sector

Next-Level Collaboration: QUBES and Bottomley Consulting group join forces to support Clinical Trial Analytics

QUBES. is a biostatistics & data science consultancy group that can support you in analyzing & exploring your clinical trial data, including QOL.

QUBES. statisticians have more than 20 years average experience in drug development for pharma or CRO. Together, they’ve contributed to dozens of regulatory submissions around the world, including in oncology where dossiers were presenting large number of QOL analyses. They’re also authors of numerous publications in journals like The Lancet, NEJM, Nature, JCO … They have experience in Immuno-Oncology, Neuroscience, Immunoscience, CV, Metabolics, etc.

QUBES. biostatisticians provide support in developing clinical plans, designing clinical trials (including sample size calculations), authoring statistical analysis plans, interpreting study results, data mining, reviewing and addressing biostatistics related questions / defending dossiers to regulatory or HTA authorities. QUBES. can also be the Sponsor’s representative when interacting with or supervising an external stats/programming CRO.

To explore how QUBES can facilitate the realization of your goals, we invite you to connect with Dr. Andrew Bottomley or reach out to QUBES directly. Our commitment is to empower you with the highest standards of biostatistical and data science expertise, ensuring your journey towards success is characterized by precision and excellence.

Contact us today, and let’s embark on this collaborative journey together.